{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:18Z","timestamp":1793679198120,"version":"4.5.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"crossref","award":["WE.15-2013-08"],"award-info":[{"award-number":["WE.15-2013-08"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish research council"},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n-stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish state support for clinical research"},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish alzheimer foundation"},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007464","name":"Torsten S\u00f6derbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007464","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Frimurarestiftelsen"},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010573","name":"Stichting Dioraphte","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010573","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-017-0335-x","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T07:17:36Z","timestamp":1516000656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"10","author":[{"given":"Flora H.","family":"Duits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"Van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"335_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368:387\u2013403.","journal-title":"Lancet"},{"key":"335_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol"},{"key":"335_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"335_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol"},{"key":"335_CR5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","volume":"68","author":"SW Scheff","year":"2007","unstructured":"Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501\u20138.","journal-title":"Neurology"},{"key":"335_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Waldo M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2016;3:12\u201320.","journal-title":"Ann Clin Transl Neurol"},{"key":"335_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement. 2016;12:719\u201332.","journal-title":"Alzheimers Dement"},{"key":"335_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jprot.2010.11.010","volume":"74","author":"AC Kroksveen","year":"2011","unstructured":"Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics. 2011;74:371\u201388.","journal-title":"J Proteomics"},{"key":"335_CR9","first-page":"769","volume":"2015","author":"A Brinkmalm","year":"1854","unstructured":"Brinkmalm A, Portelius E, Ohrfelt A, Brinkmalm G, Andreasson U, Gobom J, et al. Explorative and targeted neuroproteomics in Alzheimer\u2019s disease. Biochim Biophys Acta. 1854;2015:769\u201378.","journal-title":"Biochim Biophys Acta"},{"key":"335_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.2007.00985.x","volume":"118","author":"H Zetterberg","year":"2008","unstructured":"Zetterberg H, R\u00fcetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, et al. Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand. 2008;118:1\u201311.","journal-title":"Acta Neurol Scand"},{"key":"335_CR11","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1016\/j.jprot.2012.04.048","volume":"75","author":"A Maiolica","year":"2012","unstructured":"Maiolica A, Junger MA, Ezkurdia I, Aebersold R. Targeted proteome investigation via selected reaction monitoring mass spectrometry. J Proteomics. 2012;75:3495\u2013513.","journal-title":"J Proteomics"},{"key":"335_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1210\/er.2010-0027","volume":"32","author":"A Bartolomucci","year":"2011","unstructured":"Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011;32:755\u201397.","journal-title":"Endocr Rev"},{"key":"335_CR13","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/pmic.200300470","volume":"3","author":"O Carrette","year":"2003","unstructured":"Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer\u2019s disease. Proteomics. 2003;3:1486\u201394.","journal-title":"Proteomics"},{"key":"335_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neuron.2008.10.001","volume":"60","author":"B Sun","year":"2008","unstructured":"Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer\u2019s disease. Neuron. 2008;60:247\u201357.","journal-title":"Neuron"},{"key":"335_CR15","doi-asserted-by":"publisher","first-page":"17843","DOI":"10.1073\/pnas.0408154101","volume":"101","author":"AL Oliveira","year":"2004","unstructured":"Oliveira AL, Thams S, Lidman O, Piehl F, Hokfelt T, Karre K, et al. A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc Natl Acad Sci U S A. 2004;101:17843\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"335_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12038-010-0015-5","volume":"35","author":"L Callewaert","year":"2010","unstructured":"Callewaert L, Michiels CW. Lysozymes in the animal kingdom. J Biosci. 2010;35:127\u201360.","journal-title":"J Biosci"},{"key":"335_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tins.2005.11.003","volume":"29","author":"C Dean","year":"2006","unstructured":"Dean C, Dresbach T. Neuroligins and neurexins: linking cell adhesion, synapse formation and cognitive function. Trends Neurosci. 2006;29:21\u20139.","journal-title":"Trends Neurosci"},{"key":"335_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0896-6273(03)00463-X","volume":"39","author":"D Xu","year":"2003","unstructured":"Xu D, Hopf C, Reddy R, Cho RW, Guo L, Lanahan A, et al. Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. Neuron. 2003;39:513\u201328.","journal-title":"Neuron"},{"key":"335_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.neuron.2011.02.021","volume":"69","author":"B Zonta","year":"2011","unstructured":"Zonta B, Desmazieres A, Rinaldi A, Tait S, Sherman DL, Nolan MF, et al. A critical role for Neurofascin in regulating action potential initiation through maintenance of the axon initial segment. Neuron. 2011;69:945\u201356.","journal-title":"Neuron"},{"key":"335_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.biocel.2012.01.012","volume":"44","author":"M Kriebel","year":"2012","unstructured":"Kriebel M, Wuchter J, Trinks S, Volkmer H. Neurofascin: a switch between neuronal plasticity and stability. Int J Biochem Cell Biol. 2012;44:694\u20137.","journal-title":"Int J Biochem Cell Biol"},{"key":"335_CR21","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1128\/MCB.21.17.5970-5978.2001","volume":"21","author":"XH Zhou","year":"2001","unstructured":"Zhou XH, Brakebusch C, Matthies H, Oohashi T, Hirsch E, Moser M, et al. Neurocan is dispensable for brain development. Mol Cell Biol. 2001;21:5970\u20138.","journal-title":"Mol Cell Biol"},{"key":"335_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/bmm.12.42","volume":"6","author":"AM Fagan","year":"2012","unstructured":"Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. Biomark Med. 2012;6:455\u201376.","journal-title":"Biomark Med"},{"key":"335_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JAD-2009-0966","volume":"16","author":"SF Hansson","year":"2009","unstructured":"Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, et al. Reduced levels of amyloid-\u03b2-binding proteins in cerebrospinal fluid from Alzheimer\u2019s disease patients. J Alzheimers Dis. 2009;16:389\u201397.","journal-title":"J Alzheimers Dis"},{"key":"335_CR24","doi-asserted-by":"publisher","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","volume":"6","author":"H Jahn","year":"2011","unstructured":"Jahn H, Wittke S, Zurbig P, Raedler TJ, Arlt S, Kellmann M, et al. Peptide fingerprinting of Alzheimer\u2019s disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One. 2011;6:e26540.","journal-title":"PLoS One"},{"key":"335_CR25","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1038\/tp.2013.69","volume":"3","author":"N Mattsson","year":"2013","unstructured":"Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM, et al. CSF protein biomarkers predicting longitudinal reduction of CSF \u03b2-amyloid42 in cognitively healthy elders. Transl Psychiatry. 2013;3:e293.","journal-title":"Transl Psychiatry"},{"key":"335_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1385\/JMN:18:1-2:53","volume":"18","author":"J Marksteiner","year":"2002","unstructured":"Marksteiner J, Kaufmann WA, Gurka P, Humpel C. Synaptic proteins in Alzheimer\u2019s disease. J Mol Neurosci. 2002;18:53\u201363.","journal-title":"J Mol Neurosci"},{"key":"335_CR27","doi-asserted-by":"publisher","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","volume":"6","author":"RJ Perrin","year":"2011","unstructured":"Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer\u2019s disease. PLoS One. 2011;6:e16032.","journal-title":"PLoS One"},{"key":"335_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.neurobiolaging.2007.01.011","volume":"29","author":"AH Simonsen","year":"2008","unstructured":"Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, et al. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease. Neurobiol Aging. 2008;29:961\u20138.","journal-title":"Neurobiol Aging"},{"key":"335_CR29","doi-asserted-by":"crossref","unstructured":"Brinkmalm G, Sj\u00f6din S, Simonsen AH, Hasselbalch SG, Zetterberg H, Brinkmalm A, et al. A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer\u2019s disease. Proteomics Clin Appl. 2017. doi: 10.1002\/prca.201700131","DOI":"10.1002\/prca.201700131"},{"key":"335_CR30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM Flier van der","year":"2014","unstructured":"van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41:313\u201327.","journal-title":"J Alzheimers Dis"},{"key":"335_CR31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"335_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394.","journal-title":"J Intern Med"},{"key":"335_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"335_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jalz.2012.01.004","volume":"9","author":"W Jongbloed","year":"2013","unstructured":"Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, et al. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer\u2019s disease study. Alzheimers Dement. 2013;9:276\u201383.","journal-title":"Alzheimers Dement"},{"key":"335_CR35","doi-asserted-by":"publisher","unstructured":"Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results. Clin Chem. 2017. \n                    https:\/\/doi.org\/10.1373\/clinchem.2017.281055","DOI":"10.1373\/clinchem.2017.281055"},{"key":"335_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1021\/pr501076j","volume":"14","author":"M H\u00f6ltt\u00e4","year":"2015","unstructured":"H\u00f6ltt\u00e4 M, Minthon L, Hansson O, Holm\u00e9n-Larsson J, Pike I, Ward M, et al. An integrated workflow for multiplex CSF proteomics and peptidomics\u2014identification of candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. J Proteome Res. 2015;14:654\u201363.","journal-title":"J Proteome Res"},{"key":"335_CR37","doi-asserted-by":"publisher","first-page":"12156","DOI":"10.1523\/JNEUROSCI.1898-07.2007","volume":"27","author":"S Thakker-Varia","year":"2007","unstructured":"Thakker-Varia S, Krol JJ, Nettleton J, Bilimoria PM, Bangasser DA, Shors TJ, et al. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci. 2007;27:12156\u201367.","journal-title":"J Neurosci"},{"key":"335_CR38","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1523\/JNEUROSCI.23-34-10800.2003","volume":"23","author":"J Alder","year":"2003","unstructured":"Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci. 2003;23:10800\u20138.","journal-title":"J Neurosci"},{"key":"335_CR39","doi-asserted-by":"publisher","first-page":"9857","DOI":"10.1523\/JNEUROSCI.3145-08.2008","volume":"28","author":"O Bozdagi","year":"2008","unstructured":"Bozdagi O, Rich E, Tronel S, Sadahiro M, Patterson K, Shapiro ML, et al. The neurotrophin-inducible gene Vgf regulates hippocampal function and behavior through a brain-derived neurotrophic factor-dependent mechanism. J Neurosci. 2008;28:9857\u201369.","journal-title":"J Neurosci"},{"key":"335_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00702-011-0648-z","volume":"118","author":"M Willis","year":"2011","unstructured":"Willis M, Leitner I, Jellinger KA, Marksteiner J. Chromogranin peptides in brain diseases. J Neural Transm. 2011;118:727\u201335.","journal-title":"J Neural Transm"},{"key":"335_CR41","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.1074\/jbc.M116.761189","volume":"292","author":"J Brito-Moreira","year":"2017","unstructured":"Brito-Moreira J, Lourenco MV, Oliveira MM, Ribeiro FC, Ledo JH, Diniz LP, et al. Interaction of amyloid-\u03b2 (A\u03b2) oligomers with neurexin 2\u03b1 and neuroligin 1 mediates synapse damage and memory loss in mice. J Biol Chem. 2017;292:7327\u201337.","journal-title":"J Biol Chem"},{"key":"335_CR42","doi-asserted-by":"publisher","first-page":"12735","DOI":"10.1523\/JNEUROSCI.0575-06.2006","volume":"26","author":"MA Abad","year":"2006","unstructured":"Abad MA, Enguita M, DeGregorio-Rocasolano N, Ferrer I, Trullas R. Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-\u03b2 and is overexpressed in dystrophic neurites in Alzheimer\u2019s brain. J Neurosci. 2006;26:12735\u201347.","journal-title":"J Neurosci"},{"key":"335_CR43","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1093\/cercor\/bhx046","volume":"27","author":"DM Cummings","year":"2017","unstructured":"Cummings DM, Benway TA, Ho H, Tedoldi A, Fernandes Freitas MM, Shahab L, et al. Neuronal and peripheral pentraxins modify glutamate release and may interact in blood-brain barrier failure. Cereb Cortex. 2017;27:3437\u201348.","journal-title":"Cereb Cortex"},{"key":"335_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.brainres.2016.06.010","volume":"1646","author":"H Yan","year":"2016","unstructured":"Yan H, Zhu X, Xie J, Zhao Y, Liu X. \u03b2-Amyloid increases neurocan expression through regulating Sox9 in astrocytes: a potential relationship between Sox9 and chondroitin sulfate proteoglycans in Alzheimer\u2019s disease. Brain Res. 2016;1646:377\u201383.","journal-title":"Brain Res"},{"key":"335_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457\u201364.","journal-title":"Ann Neurol"},{"key":"335_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0197-4580(90)90059-9","volume":"11","author":"SW Scheff","year":"1990","unstructured":"Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer\u2019s disease. Neurobiol Aging. 1990;11:29\u201337.","journal-title":"Neurobiol Aging"},{"key":"335_CR47","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1523\/JNEUROSCI.3263-16.2017","volume":"37","author":"AP Schultz","year":"2017","unstructured":"Schultz AP, Chhatwal JP, Hedden T, Mormino EC, Hanseeuw BJ, Sepulcre J, et al. Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals. J Neurosci. 2017;37:4323\u201331.","journal-title":"J Neurosci"},{"key":"335_CR48","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1212\/01.wnl.0000435556.21319.e4","volume":"81","author":"CR Jack Jr","year":"2013","unstructured":"Jack Jr CR, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732\u201340.","journal-title":"Neurology"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T19:57:02Z","timestamp":1547495822000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0335-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0335-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"9 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All subjects in this study gave written informed consent for the use of their clinical data and CSF for research purposes. The study was approved by the local ethical review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the sponsors had any role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, and approval of the manuscript; or in the decision to submit the manuscript for publication. CET is a member of international advisory boards of Fujirebio and Roche and has performed contract research for Probiodrug, IBL, and Shire. PS serves or has served on the advisory boards of Novartis, Pfizer, Roche, Danone, Janssen Alzheimer Immunotherapy, Baxter, and Lundbeck. PS also has been a speaker at symposia organized by Lundbeck, Eli Lilly and Company, Merz Pharma, Pfizer, Janssen Alzheimer Immunotherapy, Danone, and Roche. PS is co-editor-in-chief of Alzheimer\u2019s Research & Therapy. PS also is a member of the scientific advisory board of the EU Joint Programme on Neurodegenerative Disease Research (JPND) and the French National Plan Alzheimer. In addition, PS acts as vice-chair of the Dutch Deltaplan for Dementia. PS receives no personal compensation for the activities mentioned above. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"5"}}